In this review, we highlight the regulation and molecular mechanism of the Hippo–YAP1/TAZ pathway in MASLD and summarize potential therapeutic strategies for MASLD by regulating Hippo–YAP1/TAZ pathway. Here, YAP1 is linked to metabolic dysfunction-associated steatotic liver disease.